

1. [Intellectual Property index: India remains near bottom](#) – The Hindu

India remains near the bottom in an international Intellectual Property (IP) index by being ranked 43rd out of 45 countries, according to a report by the U.S. Chamber of Commerce's Global Intellectual Property Center (GIPC). The report said it includes 90% of global gross domestic product, and grades countries on patents, trademarks, copyright, trade secrets, enforcement, and international treaties. Only two countries were ranked below India – Pakistan (44th) and Venezuela (45th). The U.S., the U.K., Germany, Japan, Sweden, France, Switzerland, Singapore, South Korea and Italy completed the top 10 ranks. Among the BRICS countries China was ranked 27th, South Africa (33rd), Brazil (32nd) and Russia (23rd).

1. [Intellectual Property index: India remains near bottom](#) – The Hindu
2. [Government plans first startup district with incubators](#) – The Economic Times
3. [Chronic non-communicable diseases on the rise in urban India](#) – Business Standard
4. [BioAsia meet attracts ₹3,400 cr in proposals](#) – The Hindu Business Line
5. [J&J working with Indian govt on tuberculosis treatment](#) – The Times of India
6. [Acquisitions will be critical for building Lupin's specialty drugs business: Nilesh Gupta](#) – Mint
7. [Novartis bets big on data analytics, outcome-based pricing to cut drug costs](#) – The Times of India
8. [BioAsia 2017 concludes in Hyderabad; paves way for future growth of life sciences sector in India](#) – Pharmabiz.com

The report added, "While the Indian government issued the National Intellectual Property Rights (IPR) Policy in 2016, IP-intensive industries continued to face challenges in the Indian market with regard to the scope of patentability for computer-implemented inventions, Section 3(d) of the Indian Patent Act (that prevents ever-greening of patents), and the recent High Court of Delhi decision regarding photocopying copyrighted content."

2. [Government plans first startup district with incubators](#) – The Economic Times

India will soon have its first startup district with incubation centres and about 20 tinkering labs for schools aimed at encouraging the creation of innovative solutions in agriculture, health and education. Commerce & industry minister Nirmala Sitharaman, who is a Rajya Sabha MP from Karnataka, is keen for the entire cluster to be developed in Mangalore. The government will fund the effort and ensure that roads, electricity and digital networks are provided for the one of the largest upcoming incubation facilities in the country. While the cost has not been assessed, a person familiar with the development said, "Government will put all its weight behind it in terms of making resources available. The idea is also to expand the startup drive in cities other than Bengaluru and Hyderabad." The incubation centres will provide specialised services for sectors including agriculture, medicine and pharma, along with information technology.

3. [Chronic non-communicable diseases on the rise in urban India](#) – Business Standard

Practo, the leading healthcare platform, recently released the second edition of its Annual Healthcare Map of India, which highlights some of the key consumer health concerns. Practo's 2016 Healthcare Map shows increase in patients visiting specialists due to growing concerns over chronic ailments like respiratory diseases, cardiovascular diseases, diabetes, spine, and gastric conditions. The report is a comprehensive look at the disease and illness trends across India. Annually, Practo facilitates 45M appointments on its platform. The report is based on those health care appointments that were booked across 35 cities with focus on top seven cities including Delhi &

NCR, Bangalore, Mumbai, Kolkata, Pune, Chennai and Hyderabad across 200+ medical specialties. Uniquely, the report is entirely based on actual patient actions (booking appointments) rather than surveys.

4. [BioAsia meet attracts ₹3,400 cr in proposals](#) – The Hindu Business Line

The flagship biotech conference of Telangana, BioAsia 2017, has witnessed investment proposals amounting to ₹3,400 crore. This was disclosed by Jayesh Ranjan, Principal Secretary of Industries, Commerce, IT, Electronics and Communications on the conclusion of the three-day conference here on Wednesday. In addition, there were around 1,200 trade meetings between various organisations. "It proves that Hyderabad is the leading city in life sciences in the whole country," he claimed. "We are sure that Hyderabad will continue to work towards increasing its share in global life sciences industry in the coming years." Five select start-ups showcased at the meet presented their products and services in the field of healthcare.

5. [J&J working with Indian govt on tuberculosis treatment](#) – The Times of India

Global drug major Johnson and Johnson is working with the Indian Government in the area of treatment for tuberculosis, said Paul Stoffels, Worldwide Chairman Pharmaceuticals and Chief Scientific Officer of Johnson and Johnson here today. It is a molecule we are working with the Government of India. It is Bedaquiline (drug). It is the first new molecule in last forty years (for TB). It is a very impactful drug for multi-drug therapy...we are working with the government to bring it to the people," Stoffels told reporters on the sidelines of BioAsia-2017 being held here. Last year, Telangana Government had said that it has entered into an MoU with Johnson & Johnson to work together for making the state tuberculosis free. Replying to a query, he said J and J is working on a vaccine for HIV and the result is expected in the next three years. "HIV vaccine. The study is starting this year and the outcome of that will be known in 2020," he said.

6. [Acquisitions will be critical for building Lupin's specialty drugs business: Nilesch Gupta](#) – Mint

Maker of generic (or off patent) drugs Lupin Ltd, plans to build a portfolio of specialty products for the US market through acquisitions in areas of women's health, pediatrics and neurology, managing director Nilesch Gupta said in an interview. "In the near term, we are looking at acquisitions to build our specialty business. It could be a mix of late-stage development assets, finished products portfolio or companies. We have evaluated many opportunities but what we are looking at is a strategic fit and rational valuation. Over the past 4-5 years, valuations in the specialty segment have gone up significantly but are now starting to get more rational," Gupta said. Lupin currently has just around four or five branded products in the US market. In 2015-16, the firm's branded business had revenue of \$46 million, contributing 5% to Lupin's US sales.

7. [Novartis bets big on data analytics, outcome-based pricing to cut drug costs](#) – The Times of India

With the clamour to make life saving drugs more affordable growing louder across the globe, Swiss pharma behemoth Novartis is increasingly banking on technological tools such as data analytics and deep learning to drive down the costs of drug discovery, Vasant Narasimhan, global head of drug development and chief medical officer, Novartis, said. In the near-term, the company is also toying with the idea of outcome based pricing of drugs in the US where drug pricing has come under the scanner of the Trump administration. "We want to be leaders in bringing data analytics into our development efforts, clinical trials... whether it is sensors, deep learning or machine learning, we are already doing that and increasingly rolling out these efforts. This is a top priority as we believe that it will enable us to drive down the cost of drug development," Narasimhan said, adding that Novartis' Hyderabad development centre could prove to be strategic as the company has built all these capabilities here.

8. [BioAsia 2017 concludes in Hyderabad; paves way for future growth of life sciences sector in India](#) – Pharmabiz.com

BioAsia 2017, the 14th Edition of Biotechnology and Life sciences conference, concluded successfully on the third day at HICC in Hyderabad. The third day of Bio Asia witnessed significant business

meetings held between various government and private entities and gave promising impression that the future of biotechnology and life sciences sector will flourish in a big way ahead.

On the conclusion of BioAsia 2017, Jayesh Ranjan, Principal Secretary to Government of Telangana, Industries, Commerce, IT, Electronics and Communications said, "BioAsia 2017 has given a huge platform for various stake holders relating to biotechnology and lifesciences sectors. During the past 3 days, the event has witnessed 1200 trade meetings between various organizations and grabbed investments of around Rs. 3,400 Crores. All these sum up and put Hyderabad as the leading city in Life Sciences in the whole country. We are sure that Hyderabad will continue to work towards increasing its share in global life sciences industry in the coming years."